Marseille, January 13, 2020 – Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and developing anticancer treatment drugs, today announces its ISO9001:2015 certification in research, development and clinical activities in the field of oncology. This certification marks the success of months of preparation and demonstrates the commitment of Genoscience Pharma to improve itself in a sustainable way.
“The ISO9001:2015 certification is a key demonstration of a fully integrated quality approach which reinforces the efficiency and robustness of the development programs managed by Genoscience Pharma’s team” said Dr Cyrille Drouot, Vice-President Quality & CMC.
